Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Pharma
Glenmark, Hengrui ink $1.1B deal for HER2 ADC
Both the Hengrui ADC and Enhertu use trastuzumab as the antibody guide and an exatecan derivative as the toxic payload.
Angus Liu
Sep 24, 2025 10:16am
Boehringer's lung cancer med passes muster with the FDA
Aug 8, 2025 3:52pm
ASCO: AZ, Daiichi flex Enhertu muscle in 2 cancers
Jun 2, 2025 8:00am
Pfizer partner touts HER2 ADC trial win in bladder cancer
May 12, 2025 10:59am
BioNTech works to diversify supply base ahead of oncology launch
May 5, 2025 10:36am
Enhertu drives strong efficacy in first-line breast cancer
Apr 21, 2025 10:12am
